Exenatide and Sitagliptin Decrease Interleukin 1β, Matrix Metalloproteinase 9, and Nitric Oxide Synthase 2 Gene...

Area of Science:

• Pharmacology
• Periodontology
• Endocrinology

Background:

• Glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are used for diabetes treatment.
• These drugs exhibit anti-inflammatory properties and affect bone metabolism.

Purpose of the Study:

• To investigate the effects of exenatide (GLP-1 agonist) and sitagliptin (DPP-4 inhibitor) on periodontitis in a rat model.
• To evaluate their impact on bone loss, connective tissue attachment, and collagen degradation.

Main Methods:

• Periodontitis was induced in rats using ligature insertion.
• Animals were treated with exenatide, sitagliptin, or no drug, alongside a control group.
• Evaluated blood glucose, DPP-4 levels, gene expression (Mmp9, Nos2, Il1b), bone loss, and collagen content.

Main Results:

• Exenatide and sitagliptin treatments resulted in lower weight gain but did not affect blood glucose levels.
• Sitagliptin reduced serum DPP-4 levels.
• Both drugs downregulated Mmp9, Nos2, and Il1b gene expression in gingival tissue.

Conclusions:

• Exenatide and sitagliptin did not protect against alveolar bone loss or collagen degradation in the periodontitis model.
• Despite reducing inflammatory markers, these diabetes medications were not effective in stabilizing periodontal tissues.